HHEX and chronic myelogenous leukemia, BCR-ABL1 positive: Experiments in primary cells are required to further investigate the importance of PRH phosphorylation and determine whether the restoration of PRH activity through inhibition of CK2 may be particularly of value in imatinib or dasatinib resistant CML.